Viking Therapeutics Announces Top‑Line Results for VK2735 Maintenance Study

What Happened
On September 22, 2026, Viking Therapeutics, Inc. (VKTX) announced top-line results from its maintenance study of VK2735, a GLP‑1/GIP agonist, via a press release. The company filed that press release as Exhibit 99.1 to its Form 8‑K (Item 8.01). The Form 8‑K was signed by Brian Lian, Ph.D., President and Chief Executive Officer.

Key Details

• Event date: September 22, 2026 (press release and Form 8‑K filing).
• Drug: VK2735, described as a GLP‑1/GIP agonist.
• Study type: Maintenance study — top-line (initial) results announced.
• Filing: Press release attached as Exhibit 99.1 to the Form 8‑K.

Why It Matters
Top-line clinical results are an early, material data point that can influence investor views of a biotech’s development progress and potential value. Investors should review the Exhibit 99.1 press release for the announced results and watch for follow-up disclosures (detailed data, regulatory updates, or further filings) that provide full context and implications for VK2735’s development program.